Patents by Inventor David CARLILE

David CARLILE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY
    Publication number: 20230414750
    Abstract: The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.
    Type: Application
    Filed: March 22, 2023
    Publication date: December 28, 2023
    Inventors: Maria FILIPPOU-FRYE, Joseph Nathaniel PAULSON, Leonardo ROQUE PEREIRA, Emily PICCIONE GRIFFIN, Stephen James SIMKO, III, Johanna SY, Akiko TAGAWA, Beate WULFF, Betsy Lane ALTHAUS, David CARLILE, Nassim DJEBLI
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY
    Publication number: 20220372156
    Abstract: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 24, 2022
    Applicants: Hoffmann-La Roche Inc., Roche TCRC Inc.
    Inventors: Katharina LECHNER, Linda LUNDBERG, Thomas Francis MOORE, Peter MORCOS, Martin WEISSER, Marina BACAC, Martin BARRETT, Axel BOEHNKE, David CARLILE, Nassim DJEBLI